The Adipocyte and Hemostatic Balance in Obesity
- 1 January 1998
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 18 (1), 1-6
- https://doi.org/10.1161/01.atv.18.1.1
Abstract
Lasminogen activator inhibitor 1 is the primary physiolog- ical inhibitor of plasminogen activation in vivo, and elevations in plasma PAI-1 appear to compromise normal fibrin clearance mechanisms and promote thrombosis. PAI-1 is dramatically upregulated in obesity, a complex condition associated with increased risk for myocardial infarction, accel- erated atherosclerosis, hypertension, glucose intolerance, insu- lin resistance, hyperinsulinemia, and NIDDM. In spite of the apparent link between elevated PAI-1 levels and thrombotic disease, little is known about the origin of this plasma inhibitor in obesity/NIDDM or about the signals that control its biosynthesis. Potential insights into the underlying molecular events have come from recent studies of genetically obese mice and of cultured adipocytes. These studies are reviewed here.* They emphasize the key role played by the adipocyte, a cell whose numbers, size, and metabolic activity are grossly altered in obesity/NIDDM. They also suggest that multiple cytokines, hormones, and growth factors may be involved, and they raise the possibility that the abnormal expression of other hemostatic genes by adipocytes in obesity/NIDDM may also contribute to the cardiovascular complications of this disorder. In this regard, our preliminary studies indicate that TF gene expression is elevated in the adipose tissues of the obese mouse. Properties of PAI-1Keywords
This publication has 23 references indexed in Scilit:
- Obesity--the inevitable penalty of civilisation?British Medical Bulletin, 1997
- Enhanced expression of PAI–1 in visceral fat: Possible contributor to vascular disease in obeistyNature Medicine, 1996
- Thrombogenic and Fibrinolytic Factors and Cardiovascular Risk in Non-insulin-dependent Diabetes MellitusAnnals of Medicine, 1996
- Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-alpha and lipopolysaccharide.JCI Insight, 1996
- Structure of plasminogen activator inhibitor 1 (PAI-1) and its function in fibrinolysis: an updateFibrinolysis, 1995
- Up-regulation of PAI-1 synthesis by insulin and proinsulin in HEP G2 cells but not in endothelial cellsFibrinolysis, 1995
- Transforming growth factor-?? and the pathogenesis of glomerular diseasesCurrent Opinion in Nephrology and Hypertension, 1994
- Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart StudyThe Lancet, 1993
- Insulin Therapy in Type 2 Diabetic Subjects Suppresses Plasminogen Activator Inhibitor (PAI‐1) Activity and Proinsulin‐like Molecules Independently of Glycaemic ControlDiabetic Medicine, 1993
- Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta.JCI Insight, 1991